Clinical trials: Chronic Pulmonary Aspergillosis
Chronic Obstructive Pulmonary Disease
Relationship Between Degree of Domestic Environmental Fungal Exposure and Clinical Symptoms of Patients With Chronic Obstructive Pulmonary Disease
Exposure to Aspergillus spores is associated with symptoms of asthma or airway inflammation (Chaudhary \& Marr, 2011; Smith \& Denning, 2011), leading to the possible onset of severe fungal complications with acute or chronic…
- Trial name
- BPCO-Myc (NCT05456178)
- Testing
- Electrostatic wipe
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Hospices Civils de Lyon
Chronic Pulmonary Aspergillosis
Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being
To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.
- Trial name
- CAPSULE (NCT06885905)
- Where
- 3 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Chronic Pulmonary Aspergillosis
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
This study evaluates and aims to optimize inhalation treatment with nebulized liposomal amphotericin B in patients with chronic pulmonary aspergillosis.
- Trial name
- NIMBUS (NCT07530263)
- Testing
- 12 mg of nebulised 99mTc-liposomal amphotericin B, 24 mg of nebulised 99mTc-liposomal amphotericin B, SPECT/CT scan
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Radboud University Medical Center
Chronic Pulmonary Aspergillosis
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
The goal of this clinical trial is to to evaluate the drug rezafungin in the treatment of Chronic Pulmonary Aspergillosis (CPA) in male and female patients aged 18 years and over with limited treatment options.
- Trial name
- NCT06794554
- Testing
- Rezafungin Acetate
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Mundipharma Research Limited
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs.
- Trial name
- ABPA (NCT00585364)
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
- Trial name
- NCT02879305
- Testing
- Daprodustat, rhEPO, Iron therapy
- Where
- 462 sites in United States, Argentina and 33 more
- Volunteers
- 2,964 people
- Sponsor
- GlaxoSmithKline
Aspergillosis
Voriconazole For Chronic Bronchopulmonary Aspergillosis
To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e.
- Trial name
- NCT00159822
- Testing
- Voriconazole
- Where
- 18 sites in France
- Volunteers
- 48 people
- Sponsor
- Pfizer
Allergic Bronchopulmonary Aspergillosis (ABPA)
Interest of IgE Directed Against Recombinant Antigens of Aspergillus Fumigatus in the Diagnosis of Allergic Bronchopulmonary Aspergillosis (ABPA)
Allergic Bronchopulmonary Aspergillosis is a rare pulmonary disease involving allergic mechanisms, which historically affects patients with asthma or cystic fibrosis only. It is a source of respiratory decompensation.
- Trial name
- BPCO (NCT07055230)
- Where
- France
- Volunteers
- 67 people
- Sponsor
- University Hospital, Rouen
Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD)
Immune Status and Disease Control of Inflammatory Airway Diseases
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand: 1.Whether specific immune cell patterns in the blood are linked…
- Conditions
- Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis
- Trial name
- ISDC-IAD (NCT07493629)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the…
- Conditions
- Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
- Trial name
- MIRAGE (NCT06244979)
- Testing
- Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Fungal Infection Lungs
Risk of Aspergillus Infection in Patients With Chronic Lung Disease
Large doses of systemic corticosteroids ，severe lung tissue damage and longer COPD diagnosis may increase the risk of IPA in patients with chronic structural lung disease.
- Trial name
- NCT06379568
- Testing
- No intervention
- Where
- China
- Volunteers
- 209 people
- Sponsor
- Lin Chen
Chronic Pulmonary Aspergillosis
Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or…
- Trial name
- NCT03656081
- Testing
- inhaled Ambisome®, Itraconazole
- Where
- France
- Volunteers
- 224 people
- Sponsor
- Poitiers University Hospital
Asthma, Respiratory Candidiasis
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
This study tests the effects of an experimental drug PC945 in people with asthma or other chronic respiratory diseases whose lungs are infected by Aspergillus fungi and Candida yeasts.
- Conditions
- Asthma, Respiratory Candidiasis, Respiratory Aspergillosis, COPD
- Trial name
- NCT03745196
- Testing
- PC945
- Where
- 4 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pulmocide Ltd
Cystic Fibrosis,
Evaluation of Bronchial Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)
Chronic bronchial inflammation is an important clinical feature in cystic fibrosis. Approximately 10% of patients with cystic fibrosis suffer from Allergic Bronchopulmonary Aspergillosis.
- Trial name
- ABPA (NCT00906568)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks.
- Conditions
- Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Aspergillus Tracheobronchitis
- Trial name
- NCT05897294
- Testing
- Voriconazole Inhalation Powder
- Sponsor
- TFF Pharmaceuticals, Inc.
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Pulmonary Tuberculoses, Aspergillosis
Pulmonary Aspergillosis in Tuberculosis Patients
Pulmonary tuberculosis (PTB) is the most common cause of lung destruction, contributing to coinfections development, and Aspergillosis spp. is one of the most important.
- Conditions
- Pulmonary Tuberculoses, Aspergillosis, Old Tuberculosis, Active Tuberculosis
- Trial name
- NCT05045391
- Testing
- Aspergillus IgG detection
- Where
- Uzbekistan
- Volunteers
- 200 people
- Sponsor
- Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Chronic Pulmonary Aspergillosis, Aspergillosis
Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients with chronic lung…
- Trial name
- INCAS (NCT05653193)
- Testing
- Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care, Antifungals as standard of care
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Manchester University NHS Foundation Trust
Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities.
- Trial name
- GLITZ (NCT05444946)
- Testing
- Prednisone tablet and Itraconazole, Oral itraconazole
- Where
- 2 sites in India
- Volunteers
- 104 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Pulmonary Aspergillosis
A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis
The current initial therapy for CPA is with six months of oral itraconazole. However, the response with six months of therapy has a response rate of 65-70% and has a relapse rate after stopping treatment of up to 50%.
- Trial name
- NCT04824417
- Testing
- Itraconazole 200 mg, Voriconazole 200mg
- Where
- 2 sites in India
- Volunteers
- 116 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh